Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Solomon

Showing results (161-170 of 184) with videos related to

Pageof 19
Sort By:
Therapeutic Advances in Medical Oncology|November 3, 2022
Comorbidity between lung cancer and COVID-19 pneumonia: role of immunoregulatory gene transcripts in high <i>ACE2</i>-expressing normal lungVladimir Lazar, Jacques Raynaud, Shai Magidi, et al.
Future Oncology (London, England)|January 19, 2023
A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS dataParneet Cheema, Byoung Chul Cho, Helano Freitas, et al.
European Journal of Cancer (Oxford, England : 1990)|November 16, 2018
Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case seriesEmma L Mitchell, Peter Kar Han Lau, Chloe Khoo, et al.
The Medical Journal of Australia|May 14, 2020
Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidanceRobert Weinkove, Zoe K McQuilten, Jonathan Adler, et al.
The Lancet. Oncology|September 8, 2012
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 studyD Ross Camidge, Yung-Jue Bang, Eunice L Kwak, et al.
JCO Precision Oncology|September 15, 2022
Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non-Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant TherapiesVladimir Lazar, Nicolas Girard, Eric Raymond, et al.
Critical Reviews in Oncology/Hematology|January 26, 2025
Future directions in the evaluation and management of newly diagnosed metastatic cancerEric J Lehrer, Chachrit Khunsriraksakul, Sara Garrett, et al.
The New England Journal of Medicine|October 29, 2010
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancerEunice L Kwak, Yung-Jue Bang, D Ross Camidge, et al.
Nature Medicine|November 20, 2025
Editorial Expression of Concern: Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancerChristine M Lovly, Nerina T McDonald, Heidi Chen, et al.
Nature Medicine|September 1, 2014
Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancerChristine M Lovly, Nerina T McDonald, Heidi Chen, et al.
Pageof 19

Showing results (161-170 of 184) with videos related to

Sort By:
Pageof 19
Therapeutic Advances in Medical Oncology|November 3, 2022
Comorbidity between lung cancer and COVID-19 pneumonia: role of immunoregulatory gene transcripts in high <i>ACE2</i>-expressing normal lungVladimir Lazar, Jacques Raynaud, Shai Magidi, et al.
Future Oncology (London, England)|January 19, 2023
A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS dataParneet Cheema, Byoung Chul Cho, Helano Freitas, et al.
European Journal of Cancer (Oxford, England : 1990)|November 16, 2018
Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case seriesEmma L Mitchell, Peter Kar Han Lau, Chloe Khoo, et al.
The Medical Journal of Australia|May 14, 2020
Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidanceRobert Weinkove, Zoe K McQuilten, Jonathan Adler, et al.
The Lancet. Oncology|September 8, 2012
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 studyD Ross Camidge, Yung-Jue Bang, Eunice L Kwak, et al.
JCO Precision Oncology|September 15, 2022
Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non-Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant TherapiesVladimir Lazar, Nicolas Girard, Eric Raymond, et al.
Critical Reviews in Oncology/Hematology|January 26, 2025
Future directions in the evaluation and management of newly diagnosed metastatic cancerEric J Lehrer, Chachrit Khunsriraksakul, Sara Garrett, et al.
The New England Journal of Medicine|October 29, 2010
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancerEunice L Kwak, Yung-Jue Bang, D Ross Camidge, et al.
Nature Medicine|November 20, 2025
Editorial Expression of Concern: Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancerChristine M Lovly, Nerina T McDonald, Heidi Chen, et al.
Nature Medicine|September 1, 2014
Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancerChristine M Lovly, Nerina T McDonald, Heidi Chen, et al.
Pageof 19